“Buzz on the Street” Show: Smart Decision (OTC: SDEC) Signs Letter of Intent with LBC Bioscience – Financialbuzz.com

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Smart Decision, Inc. Signs Letter of Intent (LOI) With LBC Bioscience Inc. for CBDSMARTDECISION.COM Upcoming CBD Algorithm.”

Smart Decision, Inc. (OTC: SDEC), a next-generation consumer-based LED & CBD algorithm innovator, is pleased to announce that it has signed a Letter of Intent (LOI) with LBC Bioscience Inc., a visionary in the CBD space.

Smart Decision Inc. has researched and is developing algorithms for the consumer and business LED Lighting and CBD markets.  With their patent-pending “Smart Decision” algorithms, the confusion of selecting the right product(s), whether for LED or CBD, will be significantly reduced. Ultimately, Smart Decision Inc. believes that selecting the right product the first time, dramatically cuts down on product returns and creates of positive purchasing experience for the consumer.

Anxiety disorders are one of the most common mental illnesses in the U.S., affecting nearly 40 million adults, according to the Anxiety and Depression Association of America. Anxiety disorders are highly treatable, yet only 36.9% of those suffering actually receive treatment. Generally, people with anxiety disorders are three to five times more likely to visit a doctor and six times more likely to be hospitalized for psychiatric disorders than those who do not suffer from anxiety disorders. Furthermore, the discrepancy between people who receive treatment and those who seek medical attention is alarming. Additionally, the cost of treatment and medical visits can become quite high, especially for people who lack access to adequate healthcare coverage. Typical low-cost treatments such as cognitive-behavioral therapy can cost roughly USD 100.00 or more per hour. Plus, some healthcare insurers do not provide coverage for certain medications, making it increasingly difficult for people suffering from anxiety to manage their conditions. Consequently, many people have decided to turn to CBD or cannabidiol to suppress their anxiety disorders. CBD is a derivative of cannabis, but unlike its marijuana counterpart, the compound does not cause psychotropic effects on the consumer. Instead, CBD offers a relaxing effect in addition to a handful of therapeutic benefits. As such, it is now commonly being used for health and wellness purposes, however, researchers have determined that CBD can also be used to alleviate more serious medical conditions. Notably, medical practitioners have prescribed CBD to patients to better manage symptoms associated with severe conditions such as cancer, chronic pain, Alzheimer’s, Parkinson’s and epilepsy. In particular, the use of CBD to relieve anxiety has become increasingly popular due to the sheer number of people suffering from anxiety disorders. And as a result, the global cannabidiol market is expected to increase from USD 303 Million in 2018 to USD 2.28 Billion by 2025 while registering a CAGR of 33.5%, according to data compiled by QY Research. 

The human body has many different types of receptors that are attached to cells. CBD is thought to interact with CB1 and CB2 receptors, which are most commonly found throughout the central nervous system and the peripheral nervous system, respectively. Although the exact method of how CBD affects CB1 receptors in the brain isn’t fully understood yet, researchers believe it may alter serotonin signals, according to Healthline. Serotonin is a neurotransmitter that plays a vital role in mental health as low-levels of serotonin are commonly associated with people who suffer from depression. In some cases, not having enough serotonin can also cause anxiety. For generalized anxiety disorder, the National Institute on Drug Abuse noted that CBD has been shown to reduce anxiety in animals such as rats. Moreover, according to other studies, test subjects were observed having lower behavioral signs of anxiety. Additionally, their physiological symptoms of anxiety, such as increased heart rate, also improved. Furthermore, researchers have also discovered that CBD can be used to treat other forms of anxiety such as social anxiety disorder and post-traumatic stress disorder. In 2011, a study concluded that people suffering from social anxiety disorder experienced reduced anxiety levels. On the other hand, multiple recent studies have shown that CBD helped manage PTSD symptoms such as nightmares and the replaying of negative memories. However, despite ongoing advancements within the CBD marketspace, researchers have noted that there isn’t enough evidence gathered from clinical trials of CBD to officially approve it as a medication for anxiety disorders. Regardless, consumers can simply purchase CBD-based products such as tinctures, beverages, topicals, and even flower at retailers and even online e-commerce platforms. “Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of CBD exist in the psychiatric literature,” according to an abstract of a study published in the U.S. National Library of Medicine by researchers Scott Shannon, MD, Nicole Lewis, ND, Heather Lee, PA-C, and Shannon Hughes, PhD. “Cannabidiol may hold benefit for anxiety-related disorders.”

For more information, please visit: Smart Decision Inc.

About Behind the Buzz: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

Source: https://www.financialbuzz.com/buzz-on-the-street-show-smart-decision-otc-sdec-signs-letter-of-intent-with-lbc-bioscience/